 KNOXVILLE, TN, March 31, 2021 GLOBE NEWSWIRE -- Provectus OTCQB: PVCT today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-transit melanoma ITM patients who received intralesional aka intratumoral PV-10 under a Provectus-sponsored expanded access aka compassionate use program EAP. 